Ophthalmology. Retina最新文献

{"title":"Ultra-Widefield OCT Angiography Imaging in Pediatric Microphthalmos Using Swept-Source OCT.","authors":"Bingfeng Wang, Xiuhua Liu, Lei Gao","doi":"10.1016/j.oret.2025.08.007","DOIUrl":"https://doi.org/10.1016/j.oret.2025.08.007","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for 15-Letter Visual Acuity Loss from Geographic Atrophy Progression Over One Year in the Age-Related Eye Diseases Study 2.","authors":"Emily Vance, Leon von der Emde, Souvick Mukherjee, Jintong Hou, Amitha Domalpally, Emily Y Chew, Usha Chakravarthy, Tiarnán D L Keenan","doi":"10.1016/j.oret.2025.09.003","DOIUrl":"https://doi.org/10.1016/j.oret.2025.09.003","url":null,"abstract":"<p><strong>Purpose: </strong>A change of ≥ 15 letters in best-corrected visual acuity (BCVA) is typically defined as clinically significant by regulatory agencies, but risk factors for rapid 15-letter loss in geographic atrophy (GA) are poorly understood. The purpose was to identify independent risk factors for 15-letter loss within one year in eyes with GA.</p><p><strong>Design: </strong>Post hoc analysis of the Age-Related Eye Disease Study 2.</p><p><strong>Participants: </strong>961 eyes (743 participants).</p><p><strong>Methods: </strong>Annual fundus photographs were graded for GA presence/morphology. BCVA was measured using the Early Treatment Diabetic Retinopathy Study chart. Multivariable analyses comprised logistic regression for 15-letter loss within one year, based on (i) baseline variables (demographic, BCVA, and GA morphology variables, defined at first time-point with GA), (ii) genetic variables (CFH Y402H and ARMS2), and (iii) GA enlargement rate (from first time-point with GA).</p><p><strong>Main outcome measures: </strong>15-letter loss in BCVA within one year.</p><p><strong>Results: </strong>During 1-year follow-up, BCVA declined by ≥ 15 letters in 53 eyes (5.5%). In a model with baseline variables, the risk factors were: age (adjusted odds ratio [aOR] 1.08, 95% confidence interval [CI] 1.04-1.14, p=0.0005), closer GA proximity to fovea (aOR 0.90 per 0.1 mm increase, 95% CI 0.84-0.97, p=0.005), current smoking (aOR 3.85, 1.49-9.97, p=0.005), and BCVA <20/40 (aOR 2.09, 95% CI 1.17-3.74; p=0.013). In a model with baseline variables and genotype, CFH was a risk factor (aOR 4.63, 1.27-16.9, p=0.020, 2 vs 0 risk alleles), while ARMS2 was not. In a model with baseline variables and GA enlargement rate, faster enlargement was a risk factor (aOR 1.12 per 0.1 mm/year increase, 95% CI 1.07-1.18, p<0.0001).</p><p><strong>Conclusions: </strong>We identified multiple independent risk factors for rapid, clinically significant BCVA loss in GA. We also developed clinically relevant models for different scenarios. These can guide the design and interpretation of interventional trials aimed at decreasing vision loss in GA and provide prognostic information in clinical practice. The risk factors for BCVA loss and faster GA enlargement overlap only partially, so that trial inclusion criteria, power calculations, and covariate adjustment should differ according to the choice of a functional versus structural measure as the primary endpoint.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145054868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening for Retinal Ischemic Perivascular Lesions (RIPLs) in Patients Undergoing Cardiovascular Assessment: A Cross-Sectional Study.","authors":"Victor Bellanda, Adrienne Delaney, Matthew J Schulgit, Gabriel Castilho S Barbosa, Andrea Arline, Yuka Mizuno, Nitesh Mohan, Bhairavi Rajasekar, Suraj Bala, Madina Mahmoud, Allison Winter, Bolisa Savic, Stacie Dempsey, Kimberly Baynes, Sumit Sharma, Pulkit Chaudhury, Sunil K Srivastava","doi":"10.1016/j.oret.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.oret.2025.09.002","url":null,"abstract":"<p><strong>Purpose: </strong>Retinal ischemic perivascular lesions (RIPLs) are optical coherence tomography (OCT) findings associated with chronic retinal ischemia. Previous studies have proposed that RIPLs may serve as anatomical biomarkers for cardiovascular disease, yet their clinical significance remains uncertain. This study aims to evaluate the prevalence of RIPLs in a cardiovascular clinic and assess their association with major adverse cardiovascular events (MACE).</p><p><strong>Design: </strong>Observational cross-sectional study of prospectively enrolled patients.</p><p><strong>Participants: </strong>A total of 559 patients undergoing cardiovascular ultrasound at a vascular imaging laboratory.</p><p><strong>Methods: </strong>Non-mydriatic 6×6 mm OCT-Angiography scans were obtained on the same day of ultrasound, and RIPLs were manually identified based on inner retinal layer thinning with compensatory outer nuclear layer expansion.</p><p><strong>Main outcome measures: </strong>The prevalence of RIPLs was compared between patients with and without a history of MACE, defined as prior myocardial infarction (MI), stroke, transient ischemic attack (TIA), or coronary/carotid revascularization.</p><p><strong>Results: </strong>Among 559 included patients (mean age 61.9 ± 12.5 years; 54.4% female), 26.3% had at least one RIPL. A history of MACE was present in 35.1% of patients; however, the prevalence of RIPLs did not differ significantly between those with MACE (28.6%) and those without (25.1%) (p = 0.426), despite the MACE group having a higher prevalence of traditional cardiovascular risk factors, including hypertension, dyslipidemia, diabetes, and smoking history (p < 0.05). Similarly, no significant differences were found in subgroup analyses of patients with prior MI (p = 0.688), stroke/TIA (p = 0.394), or revascularization (p = 0.369). The prevalence of RIPLs did not differ across atherosclerotic cardiovascular disease (ASCVD) risk categories in patients without prior MACE.</p><p><strong>Conclusions: </strong>In this large, prospectively enrolled cardiovascular cohort, RIPLs were found in only a quarter of eyes, providing preliminary evidence for their prevalence in this population. Additionally, RIPLs were not significantly associated with a history of MACE. While RIPLs may reflect microvascular pathology, these findings challenge prior reports linking them to broader systemic cardiovascular disease and call for prospective longitudinal studies to clarify their clinical utility in cardiovascular risk assessment.</p>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145040805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell Free DNA to Diagnose Unilateral Solitary Amelanotic Choroidal Lesions.","authors":"Jasmine H Francis, Sara Levine, Lisa R Koenig, Julia Canestraro, David H Abramson","doi":"10.1016/j.oret.2025.09.001","DOIUrl":"https://doi.org/10.1016/j.oret.2025.09.001","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melphalan Followed by Brachytherapy for Uveal Melanoma.","authors":"Gabriela Mousse de Carvalho, Mariel Souza Natividade, Rodrigo Jorge","doi":"10.1016/j.oret.2025.08.005","DOIUrl":"https://doi.org/10.1016/j.oret.2025.08.005","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fundus Depigmentation after Immunotherapy for Metastatic Uveal Melanoma.","authors":"Richard Yi, Alexandria Steggall, Elaine M Binkley","doi":"10.1016/j.oret.2025.08.003","DOIUrl":"https://doi.org/10.1016/j.oret.2025.08.003","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: Monés et al: Spontaneous soft drusen regression without atrophy and the drusen ooze (Ophthalmology Retina 2025;9:828-837).","authors":"Christine A Curcio, K Bailey Freund","doi":"10.1016/j.oret.2025.07.022","DOIUrl":"https://doi.org/10.1016/j.oret.2025.07.022","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":" ","pages":""},"PeriodicalIF":5.7,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endophthalmitis after Pars Plana Vitrectomy","authors":"Siegfried K. Wagner PhD, FRCOphth ,&nbsp;Harry Petrushkin PhD, FRCOphth ,&nbsp;Asterios Diafas MD, MSc ,&nbsp;Achini Makuloluwa MD ,&nbsp;Lyndon da Cruz PhD, FRCOphth ,&nbsp;Mahiul M.K. Muqit PhD, FRCOphth","doi":"10.1016/j.oret.2025.02.025","DOIUrl":"10.1016/j.oret.2025.02.025","url":null,"abstract":"<div><h3>Objective</h3><div>Endophthalmitis is a rare but devastating complication of pars plana vitrectomy (PPV). We assessed the incidence, profile, and prognostic factors of post-PPV exogenous endophthalmitis in a large ethnically diverse cohort over an 11-year period.</div></div><div><h3>Design</h3><div>A retrospective single-site cohort study.</div></div><div><h3>Participants</h3><div>Adult patients (aged ≥18 years) undergoing PPV at Moorfields Eye Hospital.</div></div><div><h3>Methods</h3><div>Pars plana vitrectomy procedures between January 1, 2013 and January 1, 2024 were extracted from the electronic health record and cross-referenced with all endophthalmitis cases using clinical documentation, prescription records, and incident reports.</div></div><div><h3>Main Outcome Measures</h3><div>The incidence proportion was estimated and stratified by additional procedures during PPV. Odds ratios (ORs) with 95% confidence intervals (CIs) for the association between endophthalmitis and exposures were estimated using univariable and multivariable logistic regression models.</div></div><div><h3>Results</h3><div>There were 36  179 procedures from 26  533 patients included in the analysis. The overall incidence of post-PPV endophthalmitis was 0.05% (n = 19), of which 63.2% (n = 12) were culture positive. Five cases occurred after 28 days, of which 3 had coexisting anterior segment pathology including corneal abscesses and loose sutures. Incidence figures varied from 0.05% in PPV with internal limiting membrane peel to 0.65% in those undergoing intraocular lens (IOL) exchange. Higher odds of endophthalmitis were seen with fluid tamponade (adjusted OR [aOR], 5.70; 95% CI, 1.80–18.03; <em>P</em> = 0.003) and increasingly complex secondary IOL procedures—secondary IOL insertion alone (aOR, 5.42; 95% CI, 1.23–23.97; <em>P</em> = 0.026); IOL removal (aOR, 9.81; 95% CI, 3.10–31.07; <em>P</em> = 1.0 × 10⁻⁴); and IOL exchange (aOR, 13.64; 95% CI, 4.29–43.43; <em>P</em> = 9.7 × 10⁻⁶). When adjusting for tamponade, IOL removal (aOR, 4.64; 95% CI, 1.14–18.86; <em>P</em> = 0.032) and IOL exchange (aOR, 6.24; 95% CI, 1.43–27.27; <em>P</em> = 0.015) remained significantly associated with endophthalmitis. Endophthalmitis associated with secondary IOL procedures were all culture positive (n = 3 <em>Staphylococcus</em> spp, n = 3 <em>Streptococcus</em> spp).</div></div><div><h3>Conclusions</h3><div>Although post-PPV exogenous endophthalmitis is rare, individuals undergoing PPV with IOL removal and exchange have considerably increased odds of developing endophthalmitis. Delayed cases of endophthalmitis frequently have coexisting anterior segment pathology.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosures may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 883-891"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes in Neovascular Age-related Macular Degeneration with Aflibercept 8 mg in the Phase II CANDELA Study","authors":"Jordana G. Fein MD ,&nbsp;Priya S. Vakharia MD ,&nbsp;A. Paul Chous OD ,&nbsp;Rutvi Desai OD ,&nbsp;Fabiana Q. Silva MD ,&nbsp;Kimberly Reed OD ,&nbsp;Alyson J. Berliner MD, PhD ,&nbsp;Robert Vitti MD ,&nbsp;Charles C. Wykoff MD, PhD","doi":"10.1016/j.oret.2025.03.023","DOIUrl":"10.1016/j.oret.2025.03.023","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Pages 915-918"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Wide-Field Imaging of a Large Retinal Cavernous Hemangioma in a 13-Year-Old Boy","authors":"Antoine Arandilla ,&nbsp;Elodie Bousquet MD, PhD ,&nbsp;Paul Goupillou MD","doi":"10.1016/j.oret.2025.02.006","DOIUrl":"10.1016/j.oret.2025.02.006","url":null,"abstract":"","PeriodicalId":19501,"journal":{"name":"Ophthalmology. Retina","volume":"9 9","pages":"Page e91"},"PeriodicalIF":5.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}